Clostridioides Difficile Toxin B Variant Neutralization Data

Kerisa Hall's research report from 2026 investigates the molecular basis for monoclonal antibody bezlotoxumab's reduced neutralizing activity against Clostridioides difficile toxin B variants. The report identifies four major variants (TcdB1–TcdB4) that account for approximately 99.9% of circulating C. difficile strains globally and links susceptibility to a single amino acid substitution at position 2033. The dataset is a 76.3 KB PDF published under a CC-BY-4.0 license.

Use Cases

• Study the prevalence of specific C. difficile toxin B variants based on the reported global strain distribution.
• Model antibody-antigen interactions based on the described amino acid substitution (E2033/A2033) in the neutralizing region.
• Guide the design of broad-spectrum monoclonal antibodies based on the identified susceptibility mechanism.
• Validate in silico predictions of protein structure and function for TcdB variants.

Strengths

• Report provides a specific, quantified finding that four variants account for approximately 99.9% of global C. difficile strains.
• The molecular mechanism is clearly defined, linking a single amino acid substitution (E2033/A2033) to neutralization susceptibility.
• Dataset is openly available under a permissive CC-BY-4.0 license.

Limitations

• The dataset is a single, small (76.3 KB) PDF document, not a structured data table; row and column counts are unknown.
• Column-level documentation is absent; field semantics must be inferred from the report text after download.
• Data may reflect the specific experimental and analytical focus of the single study described.

Provenance

Source

Kerisa Hall via figshare

Collection Method

Likely contains experimental results from sequence analysis and cell-based neutralization assays as described in the report.

Freshness

Last updated 2026-05-28 04:44:13.

Geography

The study references a global distribution of C. difficile strains.